Ravi Salgia - Publications

Cancer Biology University of Chicago, Chicago, IL 
Oncology, Molecular Biology

117 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, ... ... Salgia R, et al. Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 24: 6099. PMID 30510088 DOI: 10.1158/1078-0432.Ccr-18-3194  0.32
2018 Salgia R, Kulkarni P, Gill PS. EphB4: A promising target for upper Aerodigestive malignancies. Biochimica Et Biophysica Acta. PMID 29369779 DOI: 10.1016/J.Bbcan.2018.01.003  0.32
2016 Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, Ramalingam SS, Chen M, Sun SY. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Letters. PMID 27450722 DOI: 10.1016/J.Canlet.2016.07.021  0.32
2016 Rolle CE, Tan YC, Seiwert TY, Vora S, Kanteti R, Hasina R, Carey GB, Surati M, Weichselbaum RR, Lingen MW, Vokes EE, Salgia R. Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma. Oncotarget. PMID 27244893 DOI: 10.18632/Oncotarget.9640  0.32
2016 Kanteti R, Batra SK, Lennon FE, Salgia R. FAK and paxillin, two potential targets in pancreatic cancer. Oncotarget. PMID 26980710 DOI: 10.18632/Oncotarget.8040  0.32
2016 Vigneswaran J, Tan YC, Murgu SD, Won BM, Patton KA, Villaflor VM, Hoffman PC, Hensing T, Hogarth DK, Malik R, MacMahon H, Mueller J, Simon CA, Vigneswaran WT, Wigfield CH, ... ... Salgia R, et al. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. Oncotarget. PMID 26934441 DOI: 10.18632/Oncotarget.7739  0.32
2016 Kanteti R, Dhanasingh I, El-Hashani E, Riehm JJ, Stricker T, Nagy S, Zaborin A, Zaborina O, Biron D, Alverdy JC, Im HK, Siddiqui S, Padilla PA, Salgia R. C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype Cancer Biology and Therapy. 17: 91-103. DOI: 10.1080/15384047.2015.1108495  0.32
2015 Allen MJ, Kanteti R, Riehm JJ, El-Hashani E, Salgia R. Whole-animal mounts of Caenorhabditis elegans for 3D imaging using atomic force microscopy. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 26282382 DOI: 10.1016/J.Nano.2015.07.014  0.32
2015 Nocula-Lugowska M, Lugowski M, Salgia R, Kossiakoff AA. Engineering synthetic antibody inhibitors specific for LD2 or LD4 motifs of paxillin. Journal of Molecular Biology. PMID 26087144 DOI: 10.1016/J.Jmb.2015.06.004  0.32
2015 Ferguson BD, Carol Tan YH, Kanteti RS, Liu R, Gayed MJ, Vokes EE, Ferguson MK, John Iafrate A, Gill PS, Salgia R. Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer. Scientific Reports. 5: 10641. PMID 26073592 DOI: 10.1038/Srep10641  0.32
2015 Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D, Hoover R, Ou SI, Salgia R, Brennan T, Chalmers ZR, et al. Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors. Cancer Discovery. PMID 25971938 DOI: 10.1158/2159-8290.Cd-15-0285  0.32
2015 Zhang H, Wroblewski K, Jiang Y, Penney BC, Appelbaum D, Simon CA, Salgia R, Pu Y. A new PET/CT volumetric prognostic index for non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 89: 43-9. PMID 25936471 DOI: 10.1016/J.Lungcan.2015.03.023  0.32
2015 Fu P, Usatyuk PV, Lele A, Harijith A, Gregorio CC, Garcia JG, Salgia R, Natarajan V. c-Abl mediated tyrosine phosphorylation of paxillin regulates LPS-induced endothelial dysfunction and lung injury. American Journal of Physiology. Lung Cellular and Molecular Physiology. 308: L1025-38. PMID 25795725 DOI: 10.1152/Ajplung.00306.2014  0.32
2015 Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, ... ... Salgia R, et al. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2601-12. PMID 25767293 DOI: 10.1158/1078-0432.Ccr-14-2648  0.32
2015 Dikopf A, Wood K, Salgia R. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients. Expert Opinion On Drug Safety. 14: 485-93. PMID 25659177 DOI: 10.1517/14740338.2015.1007040  0.32
2015 Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, et al. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: S1-63. PMID 25535693 DOI: 10.1097/Jto.0000000000000405  0.32
2015 Kendra KL, Plummer R, Salgia R, O'Brien ME, Paul EM, Suttle AB, Compton N, Xu CF, Ottesen LH, Villalona-Calero MA. A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors. Molecular Cancer Therapeutics. 14: 461-9. PMID 25504632 DOI: 10.1158/1535-7163.Mct-14-0431  0.32
2015 Keck MK, Zuo Z, Khattri A, Stricker TP, Brown CD, Imanguli M, Rieke D, Endhardt K, Fang P, Brägelmann J, DeBoer R, El-Dinali M, Aktolga S, Lei Z, Tan P, ... ... Salgia R, et al. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 870-81. PMID 25492084 DOI: 10.1158/1078-0432.Ccr-14-2481  0.32
2014 Ferguson BD, Tretiakova MS, Lingen MW, Gill PS, Salgia R. Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition. Growth Factors (Chur, Switzerland). 32: 202-6. PMID 25391996 DOI: 10.3109/08977194.2014.980904  0.32
2014 Iida M, Brand TM, Starr MM, Huppert EJ, Luthar N, Bahrar H, Coan JP, Pearson HE, Salgia R, Wheeler DL. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Molecular Cancer. 13: 242. PMID 25344208 DOI: 10.1186/1476-4598-13-242  0.32
2014 Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, ... Salgia R, et al. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6336-45. PMID 25326232 DOI: 10.1158/1078-0432.Ccr-14-1293  0.32
2014 Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. The New England Journal of Medicine. 371: 1963-71. PMID 25264305 DOI: 10.1056/Nejmoa1406766  0.32
2014 Kanteti R, Dhanasingh I, Kawada I, Lennon FE, Arif Q, Bueno R, Hasina R, Husain AN, Vigneswaran W, Seiwert T, Kindler HL, Salgia R. MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. Plos One. 9: e105919. PMID 25221930 DOI: 10.1371/Journal.Pone.0105919  0.32
2014 Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, Toulany M, Gill PS, Salgia R, Kimple RJ, Wheeler DL. AXL mediates resistance to cetuximab therapy. Cancer Research. 74: 5152-64. PMID 25136066 DOI: 10.1158/0008-5472.Can-14-0294  0.32
2014 Lukas RV, Lesniak MS, Salgia R. Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches. Cns Oncology. 3: 61-75. PMID 25054901 DOI: 10.2217/Cns.13.66  0.32
2014 Brand TM, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, Wheeler DL. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer. Molecular Cancer Therapeutics. 13: 1356-68. PMID 24634415 DOI: 10.1158/1535-7163.Mct-13-1021  0.32
2014 Usatyuk PV, Fu P, Mohan V, Epshtein Y, Jacobson JR, Gomez-Cambronero J, Wary KK, Bindokas V, Dudek SM, Salgia R, Garcia JG, Natarajan V. Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells. The Journal of Biological Chemistry. 289: 13476-91. PMID 24634221 DOI: 10.1074/Jbc.M113.527556  0.32
2014 Salgia R, Patel P, Bothos J, Yu W, Eppler S, Hegde P, Bai S, Kaur S, Nijem I, Catenacci DV, Peterson A, Ratain MJ, Polite B, Mehnert JM, Moss RA. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1666-75. PMID 24493831 DOI: 10.1158/1078-0432.Ccr-13-2070  0.32
2014 Maitland ML, Levine MR, Lacouture ME, Wroblewski KE, Chung CH, Gordon IO, Szeto L, Ratko G, Soltani K, Kozloff MF, Hoffman PC, Salgia R, Carbone DP, Karrison TG, Vokes EE. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. Bmc Cancer. 14: 5. PMID 24386952 DOI: 10.1186/1471-2407-14-5  0.32
2014 Rolle CE, Kanteti R, Surati M, Nandi S, Dhanasingh I, Yala S, Tretiakova M, Arif Q, Hembrough T, Brand TM, Wheeler DL, Husain AN, Vokes EE, Bharti A, Salgia R. Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. Molecular Cancer Therapeutics. 13: 576-84. PMID 24327519 DOI: 10.1158/1535-7163.Mct-13-0109  0.32
2014 Hensing T, Chawla A, Batra R, Salgia R. A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Advances in Experimental Medicine and Biology. 799: 85-117. PMID 24292963 DOI: 10.1007/978-1-4614-8778-4_5  0.32
2014 Puri N, Pitman RT, Mulnix RE, Erickson T, Iness AN, Vitali C, Zhao Y, Salgia R. Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides. Cancer Letters. 343: 14-23. PMID 24041868 DOI: 10.1016/J.Canlet.2013.09.010  0.32
2013 Hasina R, Surati M, Kawada I, Arif Q, Carey GB, Kanteti R, Husain AN, Ferguson MK, Vokes EE, Villaflor VM, Salgia R. O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer. Journal of Carcinogenesis. 12: 20. PMID 24319345 DOI: 10.4103/1477-3163.120632  0.32
2013 Ferguson BD, Liu R, Rolle CE, Tan YH, Krasnoperov V, Kanteti R, Tretiakova MS, Cervantes GM, Hasina R, Hseu RD, Iafrate AJ, Karrison T, Ferguson MK, Husain AN, Faoro L, ... ... Salgia R, et al. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. Plos One. 8: e67668. PMID 23844053 DOI: 10.1371/Journal.Pone.0067668  0.32
2013 Shieh JM, Tang YA, Yang TH, Chen CY, Hsu HS, Tan YH, Salgia R, Wang YC. Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis. International Journal of Medical Sciences. 10: 988-94. PMID 23801885 DOI: 10.7150/Ijms.5944  0.32
2013 Kawada I, Hasina R, Lennon FE, Bindokas VP, Usatyuk P, Tan YH, Krishnaswamy S, Arif Q, Carey G, Hseu RD, Robinson M, Tretiakova M, Brand TM, Iida M, Ferguson MK, ... ... Salgia R, et al. Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer. Cancer Biology & Therapy. 14: 679-91. PMID 23792636 DOI: 10.4161/Cbt.25091  0.32
2013 Liu R, Ferguson BD, Zhou Y, Naga K, Salgia R, Gill PS, Krasnoperov V. EphB4 as a therapeutic target in mesothelioma. Bmc Cancer. 13: 269. PMID 23721559 DOI: 10.1186/1471-2407-13-269  0.32
2013 Traynor AM, Weigel TL, Oettel KR, Yang DT, Zhang C, Kim K, Salgia R, Iida M, Brand TM, Hoang T, Campbell TC, Hernan HR, Wheeler DL. Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 81: 138-41. PMID 23628526 DOI: 10.1016/J.Lungcan.2013.03.020  0.32
2013 Zhao Y, Zhao J, Mialki RK, Wei J, Spannhake EW, Salgia R, Natarajan V. Lipopolysaccharide-induced phosphorylation of c-Met tyrosine residue 1003 regulates c-Met intracellular trafficking and lung epithelial barrier function. American Journal of Physiology. Lung Cellular and Molecular Physiology. 305: L56-63. PMID 23624790 DOI: 10.1152/Ajplung.00417.2012  0.32
2013 Diamond JR, Salgia R, Varella-Garcia M, Kanteti R, LoRusso PM, Clark JW, Xu LG, Wilner K, Eckhardt SG, Ching KA, Lira ME, Schoenmakers EF, Christensen JG, Camidge DR. Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: e254-8. PMID 23610116 DOI: 10.1200/Jco.2012.46.4289  0.32
2013 Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3068-77. PMID 23553849 DOI: 10.1158/1078-0432.Ccr-12-3381  0.32
2013 Brägelmann J, Dagogo-Jack I, El Dinali M, Stricker T, Brown CD, Zuo Z, Khattri A, Keck M, McNerney ME, Longnecker R, Bieging K, Kocherginsky M, Alexander K, Salgia R, Lingen MW, et al. Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA. Oral Oncology. 49: 525-33. PMID 23490885 DOI: 10.1016/J.Oraloncology.2013.02.003  0.32
2013 Ephstein Y, Singleton PA, Chen W, Wang L, Salgia R, Kanteti P, Dudek SM, Garcia JG, Jacobson JR. Critical role of S1PR1 and integrin β4 in HGF/c-Met-mediated increases in vascular integrity. The Journal of Biological Chemistry. 288: 2191-200. PMID 23212923 DOI: 10.1074/Jbc.M112.404780  0.32
2013 Hasina R, Mollberg N, Kawada I, Mutreja K, Kanade G, Yala S, Surati M, Liu R, Li X, Zhou Y, Ferguson BD, Nallasura V, Cohen KS, Hyjek E, Mueller J, ... ... Salgia R, et al. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Research. 73: 184-94. PMID 23100466 DOI: 10.1158/0008-5472.Can-12-0915  0.32
2012 Carey GB, Kazantsev S, Surati M, Rolle CE, Kanteti A, Sadiq A, Bahroos N, Raumann B, Madduri R, Dave P, Starkey A, Hensing T, Husain AN, Vokes EE, Vigneswaran W, ... ... Salgia R, et al. Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma. Bmj Open. 2. PMID 23103606 DOI: 10.1136/Bmjopen-2012-001620  0.32
2012 Mollberg NM, Parsad NM, Armato SG, Vigneswaran J, Kindler HL, Sensakovic WF, Salgia R, Silverstein JC, Vigneswaran WT. Three-dimensional stereoscopic volume rendering of malignant pleural mesothelioma. International Surgery. 97: 65-70. PMID 23102002 DOI: 10.9738/Cc66.1  0.32
2012 Kalari S, Moolky N, Pendyala S, Berdyshev EV, Rolle C, Kanteti R, Kanteti A, Ma W, He D, Husain AN, Kindler HL, Kanteti P, Salgia R, Natarajan V. Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation. Plos One. 7: e45330. PMID 23028939 DOI: 10.1371/Journal.Pone.0045330  0.32
2012 Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Jänne PA, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. The Lancet. Oncology. 13: 1011-9. PMID 22954507 DOI: 10.1016/S1470-2045(12)70344-3  0.32
2012 Pietanza MC, Gadgeel SM, Dowlati A, Lynch TJ, Salgia R, Rowland KM, Wertheim MS, Price KA, Riely GJ, Azzoli CG, Miller VA, Krug LM, Kris MG, Beumer JH, Tonda M, et al. Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 856-65. PMID 22722787 DOI: 10.1097/Jto.0B013E31824C943F  0.32
2012 Jaklitsch MT, Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, MacMahon H, Mulshine JL, Munden RF, Salgia R, Strauss GM, Swanson SJ, Travis WD, Sugarbaker DJ. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. The Journal of Thoracic and Cardiovascular Surgery. 144: 33-8. PMID 22710039 DOI: 10.1016/J.Jtcvs.2012.05.060  0.32
2012 Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, MacMahon H, Mulshine JL, Munden RF, Salgia R, Strauss GM, Sugarbaker DJ, Swanson SJ, Travis WD, Jaklitsch MT. Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance. The Journal of Thoracic and Cardiovascular Surgery. 144: 25-32. PMID 22710038 DOI: 10.1016/J.Jtcvs.2012.05.059  0.32
2012 Kanteti R, Krishnaswamy S, Catenacci D, Tan YH, EL-Hashani E, Cervantes G, Husain AN, Tretiakova M, Vokes EE, Huet H, Salgia R. Differential expression of RON in small and non-small cell lung cancers. Genes, Chromosomes & Cancer. 51: 841-51. PMID 22585712 DOI: 10.1002/Gcc.21968  0.32
2012 Chiappori AA, Schreeder MT, Moezi MM, Stephenson JJ, Blakely J, Salgia R, Chu QS, Ross HJ, Subramaniam DS, Schnyder J, Berger MS. A phase i trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer British Journal of Cancer. 106: 839-845. PMID 22333598 DOI: 10.1038/Bjc.2012.21  0.32
2012 Rehman J, Zhang HJ, Toth PT, Zhang Y, Marsboom G, Hong Z, Salgia R, Husain AN, Wietholt C, Archer SL. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 26: 2175-86. PMID 22321727 DOI: 10.1096/Fj.11-196543  0.32
2012 Doçi CL, Mankame TP, Langerman A, Ostler KR, Kanteti R, Best T, Onel K, Godley LA, Salgia R, Lingen MW. Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer. International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists. 31: 15-24. PMID 22123719 DOI: 10.1097/Pgp.0B013E318220Ba16  0.32
2012 Cohen EE, Subramanian J, Gao F, Szeto L, Kozloff M, Faoro L, Karrison T, Salgia R, Govindan R, Vokes EE. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clinical Lung Cancer. 13: 123-8. PMID 22100149 DOI: 10.1016/J.Cllc.2011.10.001  0.32
2012 Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shih MC, Shimada N, Chen S, Salgia R, Appelbaum DE, Suzuki K, Chen CT, Pu Y. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. 39: 27-38. PMID 21946983 DOI: 10.1007/s00259-011-1934-6  0.32
2012 Hasina R, Mutreja K, Kawada I, Kanteti R, Arif Q, Liu R, Li X, Zhou Y, Hyjek E, Lingen MW, Mueller J, Waxman I, Villaflor V, Ferguson M, Vokes EE, ... ... Salgia R, et al. Abstract 1861: EPHB4 as a potential therapeutic target for esophageal cancer Cancer Research. 72: 1861-1861. DOI: 10.1158/1538-7445.Am2012-1861  0.32
2011 Nwizu T, Kanteti R, Kawada I, Rolle C, Vokes EE, Salgia R. Crizotinib (PF02341066) as a ALK /MET inhibitor- Special Emphasis as a Therapeutic Drug Against Lung Cancer. Drugs of the Future. 36: 91-99. PMID 26412935 DOI: 10.1358/Dof.2011.036.02.1584112  0.32
2011 Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJ. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4803-10. PMID 22042947 DOI: 10.1200/Jco.2011.35.4928  0.32
2011 Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. The Lancet. Oncology. 12: 1004-12. PMID 21933749 DOI: 10.1016/S1470-2045(11)70232-7  0.32
2011 Ramalingam SS, Davies AM, Longmate J, Edelman MJ, Lara PN, Vokes EE, Villalona-Calero M, Gitlitz B, Reckamp K, Salgia R, Wright JJ, Belani CP, Gandara DR. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 1741-5. PMID 21716143 DOI: 10.1097/Jto.0B013E318225924C  0.32
2011 Glubb DM, Cerri E, Giese A, Zhang W, Mirza O, Thompson EE, Chen P, Das S, Jassem J, Rzyman W, Lingen MW, Salgia R, Hirsch FR, Dziadziuszko R, Ballmer-Hofer K, et al. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5257-67. PMID 21712447 DOI: 10.1158/1078-0432.Ccr-11-0379  0.32
2011 Shumway D, Corbin K, Salgia R, Hoffman P, Villaflor V, Malik RM, Haraf DJ, Vigneswaren WT, Shaikh AY, Connell PP, Ferguson MK, Salama JK. Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 74: 446-50. PMID 21676484 DOI: 10.1016/J.Lungcan.2011.05.003  0.32
2011 Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, Camidge DR, Solomon BJ, Maki RG, Bang YJ, Kim DW, Christensen J, Tan W, Wilner KD, Salgia R, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 942-6. PMID 21623265 DOI: 10.1097/Jto.0B013E31821528D3  0.32
2011 Surati M, Robinson M, Nandi S, Faoro L, Demchuk C, Rolle CE, Kanteti R, Ferguson BD, Hasina R, Gangadhar TC, Salama AK, Arif Q, Kirchner C, Mendonca E, Campbell N, ... ... Salgia R, et al. Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database. Journal of Clinical Bioinformatics. 1: 1-11. PMID 21603121 DOI: 10.1186/2043-9113-1-8  0.32
2011 Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, Pradhan R, Qian J, et al. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 1418-25. PMID 21597387 DOI: 10.1097/Jto.0B013E318220C93E  0.32
2011 Mollberg N, Surati M, Demchuk C, Fathi R, Salama AK, Husain AN, Hensing T, Salgia R. Mind-mapping for lung cancer: towards a personalized therapeutics approach. Advances in Therapy. 28: 173-94. PMID 21337123 DOI: 10.1007/S12325-010-0103-9  0.32
2011 Edelman MJ, Otterson G, Leach J, Malpass T, Salgia R, Jones D, Mody TD, Govindan R. Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 786-9. PMID 21289521 DOI: 10.1097/Jto.0B013E31820A443F  0.32
2011 Mathew B, Lennon FE, Siegler J, Mirzapoiazova T, Mambetsariev N, Sammani S, Gerhold LM, LaRiviere PJ, Chen CT, Garcia JG, Salgia R, Moss J, Singleton PA. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesthesia and Analgesia. 112: 558-67. PMID 21156980 DOI: 10.1213/Ane.0B013E31820568Af  0.32
2011 Reddy MM, Fernandes MS, Salgia R, Levine RL, Griffin JD, Sattler M. NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases. Leukemia. 25: 281-9. PMID 21072051 DOI: 10.1038/Leu.2010.263  0.32
2010 Ou SH, Bazhenova L, Camidge DR, Solomon BJ, Herman J, Kain T, Bang YJ, Kwak EL, Shaw AT, Salgia R, Maki RG, Clark JW, Wilner KD, Iafrate AJ. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 2044-6. PMID 21102269 DOI: 10.1097/Jto.0B013E318200F9Ff  0.32
2010 Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, ... ... Salgia R, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. The New England Journal of Medicine. 363: 1693-703. PMID 20979469 DOI: 10.1056/Nejmoa1006448  0.32
2010 Faoro L, Singleton PA, Cervantes GM, Lennon FE, Choong NW, Kanteti R, Ferguson BD, Husain AN, Tretiakova MS, Ramnath N, Vokes EE, Salgia R. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. The Journal of Biological Chemistry. 285: 18575-85. PMID 20360610 DOI: 10.1074/Jbc.M109.075085  0.32
2010 Tan YH, Krishnaswamy S, Nandi S, Kanteti R, Vora S, Onel K, Hasina R, Lo FY, El-Hashani E, Cervantes G, Robinson M, Hsu HS, Kales SC, Lipkowitz S, Karrison T, ... ... Salgia R, et al. CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. Plos One. 5: e8972. PMID 20126411 DOI: 10.1371/Journal.Pone.0008972  0.32
2010 Shah A, Singh H, Sachdev V, Lee J, Yotsukura S, Salgia R, Bharti A. Differential serum level of specific haptoglobin isoforms in small cell lung cancer Current Proteomics. 7: 49-56. DOI: 10.2174/157016410790979635  0.32
2009 Faoro L, Cervantes GM, Ferguson BD, Seiwert TY, Yala S, Vigneswaran WT, Westerhoff M, Tretiakova MS, Ferguson MK, Moura GL, Husain AN, Vokes EE, Salgia R. MET/PKCbeta expression correlate with metastasis and inhibition is synergistic in lung cancer. Journal of Carcinogenesis. 8: 15. PMID 19955662 DOI: 10.4103/1477-3163.57857  0.32
2009 Krishnaswamy S, Kanteti R, Duke-Cohan JS, Loganathan S, Liu W, Ma PC, Sattler M, Singleton PA, Ramnath N, Innocenti F, Nicolae DL, Ouyang Z, Liang J, Minna J, Kozloff MF, ... ... Salgia R, et al. Ethnic differences and functional analysis of MET mutations in lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5714-23. PMID 19723643 DOI: 10.1158/1078-0432.Ccr-09-0070  0.32
2009 Mascarenhas JB, Young KP, Littlejohn EL, Yoo BK, Salgia R, Lang D. PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene. The Journal of Biological Chemistry. 284: 27524-32. PMID 19651775 DOI: 10.1074/Jbc.M109.047209  0.32
2009 Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, ... Salgia R, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Research. 69: 3021-31. PMID 19318576 DOI: 10.1158/0008-5472.Can-08-2881  0.32
2009 Kanteti R, Nallasura V, Loganathan S, Tretiakova M, Kroll T, Krishnaswamy S, Faoro L, Cagle P, Husain AN, Vokes EE, Lang D, Salgia R. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Laboratory Investigation; a Journal of Technical Methods and Pathology. 89: 301-14. PMID 19139719 DOI: 10.1038/Labinvest.2008.168  0.32
2009 Tang Z, Jiang S, Du R, Petri ET, El-Telbany A, Chan PS, Kijima T, Dietrich S, Matsui K, Kobayashi M, Sasada S, Okamoto N, Suzuki H, Kawahara K, Iwasaki T, ... ... Salgia R, et al. Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity. Oncogene. 28: 518-33. PMID 19015641 DOI: 10.1038/Onc.2008.411  0.32
2009 Posadas EM, Al-Ahmadie H, Robinson VL, Jagadeeswaran R, Otto K, Kasza KE, Tretiakov M, Siddiqui J, Pienta KJ, Stadler WM, Rinker-Schaeffer C, Salgia R. FYN is overexpressed in human prostate cancer. Bju International. 103: 171-7. PMID 18990162 DOI: 10.1111/J.1464-410X.2008.08009.X  0.32
2008 Faoro L, Loganathan S, Westerhoff M, Modi R, Husain AN, Tretiakova M, Seiwert T, Kindler HL, Vokes EE, Salgia R. Protein kinase C beta in malignant pleural mesothelioma. Anti-Cancer Drugs. 19: 841-8. PMID 18765998 DOI: 10.1097/Cad.0B013E32830Ce506  0.32
2008 Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, Seiwert T, Christensen JG, Jagadeeswaran R, Krausz T, Vokes EE, Husain AN, Salgia R. Expression and mutational analysis of MET in human solid cancers. Genes, Chromosomes & Cancer. 47: 1025-37. PMID 18709663 DOI: 10.1002/Gcc.20604  0.32
2008 Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, Morse LK, Ostler PA, Johnson BE, Jänne PA. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 113: 808-14. PMID 18543326 DOI: 10.1002/Cncr.23617  0.32
2008 Menezes RJ, Cheney RT, Husain A, Tretiakova M, Loewen G, Johnson CS, Jayaprakash V, Moysich KB, Salgia R, Reid ME. Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 17: 1104-10. PMID 18483332 DOI: 10.1158/1055-9965.Epi-07-2713  0.32
2008 Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, Salgia R, Stadler WM, Vokes EE, Fleming GF. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecologic Oncology. 110: 49-55. PMID 18423560 DOI: 10.1016/J.Ygyno.2008.02.009  0.32
2008 Siddiqui SS, Loganathan S, Krishnaswamy S, Faoro L, Jagadeeswaran R, Salgia R. C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes. Cancer Biology & Therapy. 7: 856-63. PMID 18340114 DOI: 10.4161/Cbt.7.6.5842  0.32
2008 Jagadeeswaran R, Surawska H, Krishnaswamy S, Janamanchi V, Mackinnon AC, Seiwert TY, Loganathan S, Kanteti R, Reichman T, Nallasura V, Schwartz S, Faoro L, Wang YC, Girard L, Tretiakova MS, ... ... Salgia R, et al. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Research. 68: 132-42. PMID 18172305 DOI: 10.1158/0008-5472.Can-07-1998  0.32
2008 Koon EC, Ma PC, Salgia R, Welch WR, Christensen JG, Berkowitz RS, Mok SC. Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 18: 976-84. PMID 18021219 DOI: 10.1111/J.1525-1438.2007.01135.X  0.32
2008 Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL, Salgia R, Sugarbaker DJ, Bueno R. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemotherapy and Pharmacology. 61: 549-58. PMID 17522864 DOI: 10.1007/S00280-007-0500-1  0.32
2007 Hahn O, Salgia R. Non-receptor tyrosine kinase inhibitors in lung cancer. Anti-Cancer Agents in Medicinal Chemistry. 7: 633-42. PMID 18045058 DOI: 10.2174/187152007784111322  0.32
2007 Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN, Salgia R. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. British Journal of Cancer. 97: 368-77. PMID 17667909 DOI: 10.1038/Sj.Bjc.6603884  0.32
2007 Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande Woude GF, Tretiakova MS, Lengyel E. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Research. 67: 1670-9. PMID 17308108 DOI: 10.1158/0008-5472.Can-06-1147  0.32
2007 Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, Salgia R, Posther KE, Nguyen B, Haraf DJ, Vokes EE. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 515-22. PMID 17255273 DOI: 10.1158/1078-0432.Ccr-06-1058  0.32
2006 Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R. Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas Clinical Cancer Research. 12: 7261-7270. PMID 17189397 DOI: 10.1158/1078-0432.Ccr-06-0874  0.32
2006 Ahmed SM, Salgia R. Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology (Carlton, Vic.). 11: 687-92. PMID 17052295 DOI: 10.1111/J.1440-1843.2006.00887.X  0.32
2006 Choong NW, Dietrich S, Seiwert TY, Tretiakova MS, Nallasura V, Davies GC, Lipkowitz S, Husain AN, Salgia R, Ma PC. Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nature Clinical Practice. Oncology. 3: 50-7; quiz 1 p follo. PMID 16407879 DOI: 10.1038/Ncponc0400  0.32
2006 Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberti R, Paganuzzi M, Puntoni R, Kratzke RA, Gordon GJ, Sugarbaker DJ, Bueno R, Janamanchi V, ... ... Salgia R, et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Research. 66: 352-61. PMID 16397249 DOI: 10.1158/0008-5472.Can-04-4567  0.32
2005 Chu F, Barkinge J, Hawkins S, Gudi R, Salgia R, Kanteti PV. Expression of Siva-1 protein or its putative amphipathic helical region enhances cisplatin-induced apoptosis in breast cancer cells: effect of elevated levels of BCL-2. Cancer Research. 65: 5301-9. PMID 15958577 DOI: 10.1158/0008-5472.Can-04-3270  0.32
2005 Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, Richards W, Sugarbaker D, Husain AN, Christensen JG, Salgia R. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Research. 65: 1479-88. PMID 15735036 DOI: 10.1158/0008-5472.Can-04-2650  0.32
2004 Ma PC, Tretiakova MS, Jagadeeswaran R, Jagadeesh S, Nallasura V, Kindler HL, Lingen M, Vokes EE, Husain A, Salgia R. Role of c-MET in lung cancer, malignant mesothelioma, and head and neck cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 9539. PMID 28016812 DOI: 10.1200/Jco.2004.22.14_Suppl.9539  0.32
2004 Mukhopadhyay NK, Gilchrist D, Gordon GJ, Chen CJ, Bueno R, Lu ML, Salgia R, Sugarbaker DJ, Jaklitsch MT. Integrin-dependent protein tyrosine phosphorylation is a key regulatory event in collagen-IV-mediated adhesion and proliferation of human lung tumor cell line, Calu-1. The Annals of Thoracic Surgery. 78: 450-7. PMID 15276495 DOI: 10.1016/J.Athoracsur.2004.01.042  0.32
2003 Jafri NF, Ma PC, Maulik G, Salgia R. Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer. Journal of Environmental Pathology, Toxicology and Oncology : Official Organ of the International Society For Environmental Toxicology and Cancer. 22: 147-65. PMID 14529091 DOI: 10.1615/Jenvpathtoxoncol.V22.I3.10  0.32
2003 Brown JR, Wieczorek TJ, Shaffer K, Salgia R. Small-cell cancers, and an unusual reaction to chemotherapy: Case 1. Extrapulmonary small-cell carcinoma arising in the prostate Journal of Clinical Oncology. 21: 2437-2439. PMID 12805344 DOI: 10.1200/Jco.2003.081.03  0.32
2003 Trie HY, Jaklitsch MT, Shaffer K, Weinstein M, Salgia R. Case 4. Primary lymphoepithelioma-like carcinoma of the lung Journal of Clinical Oncology. 21: 2220-2222. PMID 12775751 DOI: 10.1200/Jco.2003.09.088  0.32
2003 Ebert BL, Niemierko E, Shaffer K, Salgia R. Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer Oncologist. 8: 69-75. PMID 12604733 DOI: 10.1634/Theoncologist.8-1-69  0.32
2003 Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, Lukanich J, Bueno R, Wain J, Mathisen D, Wright C, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 624-30. PMID 12586798 DOI: 10.1200/Jco.2003.03.091  0.32
2002 Sattler M, Pride YB, Quinnan LR, Verma S, Malouf NA, Husson H, Salgia R, Lipkowitz S, Griffin JD. Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells Oncogene. 21: 1423-1433. PMID 11857085 DOI: 10.1038/Sj.Onc.1205202  0.32
2000 Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE, Salgia R. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 19: 3521-8. PMID 10918610 DOI: 10.1038/Sj.Onc.1203698  0.32
2000 Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, Winkler T, Greenfield EA, Salgia R, Griffin JD. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells Journal of Biological Chemistry. 275: 24273-24278. PMID 10833515 DOI: 10.1074/Jbc.M002094200  0.32
1999 Thomas JW, Cooley MA, Broome JM, Salgia R, Griffin JD, Lombardo CR, Schaller MD. The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin Journal of Biological Chemistry. 274: 36684-36692. PMID 10593973 DOI: 10.1074/Jbc.274.51.36684  0.32
1999 Salgia R, Quackenbush E, Lin J, Souchkova N, Sattler M, Ewaniuk DS, Klucher KM, Daley GQ, Kraeft SK, Sackstein R, Alyea EP, von Andrian UH, Chen LB, Gutierrez-Ramos JC, Pendergast AM, et al. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Blood. 94: 4233-46. PMID 10590068  0.32
1999 Salgia R, Li JL, Ewaniuk DS, Wang YB, Sattler M, Chen WC, Richards W, Pisick E, Shapiro GI, Rollins BJ, Chen LB, Griffin JD, Sugarbaker DJ. Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility Oncogene. 18: 67-77. PMID 9926921 DOI: 10.1038/Sj.Onc.1202273  0.32
1994 Salgia R, Demetri GD, Kaplan WD. Changes in Tc-99m radionuclide bone scan images and peripheralization of marrow hematopoietic activity associated with the administration of granulocyte colony stimulating factor as an adjunct to dose-intensified chemotherapy for breast cancer: A case report Cancer. 74: 1887-1890. PMID 7521785 DOI: 10.1002/1097-0142(19941001)74:7<1887::AID-CNCR2820740710>3.0.CO;2-6  0.32
1993 Salgia R, Becker JH, Sayeed MM. Altered membrane fluidity in rat hepatocytes during endotoxic shock Molecular and Cellular Biochemistry. 121: 143-148. PMID 8316231 DOI: 10.1007/Bf00925973  0.32
Show low-probability matches.